Across TCGA pan-cancer cohorts, MIR4675 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR4675’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where MIR4675 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR4675 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.
PRAD and THCA are the cancer types where MIR4675 tumor–normal differential expression is most reproducible.